Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.

CONCLUSIONS: The combination of trametinib and GSK2141795 was feasible but required dose holds and modifications for adverse events; however, anti-cancer activity was minimal, even in patients with PI3K or RAS pathway alterations. Although the study was terminated early after GSK2141795 development was halted, the findings in these 14 patients do not support further development of this combination in cervical cancer. PMID: 31118140 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31118140?dopt=Abstract

Source: Gynecologic Oncology - May 19, 2019 Category: Cancer & Oncology Authors: Liu JF, Gray KP, Wright AA, Campos S, Konstantinopoulos PA, Peralta A, MacNeill K, Morrissey S, Whalen C, Dillon D, Matulonis UA Tags: Gynecol Oncol Source Type: research